A $50 million Series B extension investment was secured by Grey Wolf Therapeutics, a clinical-stage biotechnology firm situated in Oxford, UK, that uses antigen modulation medicines.
Investors
- The Life Sciences team at ICG (raised a total of $99 million)
- Pfizer Ventures
- Andera Partners
- Canaan
- Earlybird Venture Capital
- Oxford Science Enterprises
- British Patient Capital
Use of funds
The funds will be used by the company to extend the reach of its current Phase 1/2 clinical trial of its lead immuno-oncology candidate, GRWD5769, across various solid tumor types. Additionally, the funds will be used to further research and development (R&D) of the company’s adaptable antigen modulation approach into treatments for indications related to autoimmune diseases.
About Grey Wolf Therapeutics
Grey Wolf Therapeutics is a clinical-stage biotechnology business that is focused on medication research and development. The firm is led by CEO Peter Joyce and offers a therapeutic strategy that utilizes an antigen modulation platform. A powerful and selective oral ERAP1 inhibitor, GRWD5769 is the company’s flagship clinical development candidate and has shown the ability to trigger a differentiated immune response against tumors. Preclinical research on GRWD0715, a second ERAP1 inhibitor, is progressing as a possible autoimmune disease therapy. With an ERAP2 drug discovery initiative and by therapeutically targeting new cancer antigens created by ERAP1 inhibitors with MHC Class I directed therapeutics, such as soluble T cell receptor (TCR) and TCR mimic bispecifics, the business is also capitalizing on its leadership in neoantigen production.
